Video
Dr. Garon on the Efficacy of Datopotamab Deruxtecan in NSCLC
Author(s):
Edward B. Garon, MD, discusses the efficacy of datopotamab deruxtecan in patients with non–small cell lung cancer, as reported in the phase 1 TROPION-PanTumor01 trial.
Edward B. Garon, MD, professor of medicine, Division of Hematology/Oncology, Department of Medicine, Geffen School of Medicine at UCLA, discusses the efficacy of datopotamab deruxtecan (DS-1062a) in patients with non–small cell lung cancer (NSCLC), as reported in the phase 1 TROPION-PanTumor01 trial (NCT03401385).
TROPION-PanTumor01, data of which were presented during the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer, is a large study examining the agent in patients with other solid tumor cohorts in addition to NSCLC, according to Garon.
The study includes dose-expansion cohorts in which the agent is being administered at the following doses: 4 mg/kg (n = 50), 6 mg/kg (n = 50), and 8 mg/kg (n = 80). Notably, efficacy was observed at all dose levels in this heavily pretreated patient population, and was not limited to the highest dose of 8 mg/kg, Garon says.
Ultimately, the 8-mg/kg dose was associated with more toxicity, and the 6-mg/kg dose was chosen to be examined in further studies, Garon notes. Moreover, response rates experienced at the 6-mg/kg dose and 4-mg/kg doses were similar, at 28% and 24%, respectively, Garon concludes.
